RUBY 0.09 Rubius Therapeutics, Inc.
| Range: | 0.0032-0.3763 | Vol Avg: | 99535 | Last Div: | 0 | Changes: | 0.08 |
| Beta: | 2.21 | Cap: | 0.01B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Wed Jul 18 2018 | Empoloyees: | 6 | ||
| CUSIP: | 78116T103 | CIK: | 0001709401 | ISIN: | US78116T1034 | Country: | US |
| CEO: | Dr. Laurence A. Turka M.D. | Website: | https://www.rubiustx.com | ||||
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow